Renal Cell Carcinoma Development and miRNAs: A Possible Link to the EGFR Pathway

• Ljungberg B , CampbellSC, ChoiHY et al. The epidemiology of renal cell carcinoma. Eur. Urol. 60(4), 615–621 (2011).
   PubMed Web of Science ®Google Scholar
• Ljungberg B , CowanNC, HanburyDC et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur. Urol. 58(3), 398–406 (2010).
   PubMed Web of Science ®Google Scholar
• Bex A , JonaschE, KirkaliZ et al. Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials. Eur. Urol. 58(6), 819–828 (2010).
   PubMed Web of Science ®Google Scholar
• Eble JN , SauterG, EpsteinJI, SesterhennIA. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. IARC Press, Lyon, France (2004).
   Google Scholar
• Szymanska K , MooreLE, RothmanN et al. TP53, EGFR, and KRAS mutations in relation to VHL inactivation and lifestyle risk factors in renal-cell carcinoma from central and eastern Europe. Cancer Lett.293(1), 92–98 (2010).
   PubMed Web of Science ®Google Scholar
• Patard JJ , PignotG, EscudierB et al. ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. Eur. Urol. 60(4), 684–690 (2011).
   PubMed Web of Science ®Google Scholar
• Staehler M , HasekeN, SchoepplerG, StadlerT, GratzkeC, StiefCG. Modern therapeutic approaches in metastatic renal cell carcinoma. EAU-EBU Update Series5(1), 26–37 (2007).
   Google Scholar
• Redova M , SvobodaM, SlabyO. MicroRNAs and their target gene networks in renal cell carcinoma. Biochem. Biophys. Res. Commun.405(2), 153–156 (2011).
   PubMed Web of Science ®Google Scholar
• Chou A , ToonC, PickettJ, GillAJ. von Hippel-Lindau syndrome. Front. Horm. Res.41, 30–49 (2013).
   PubMed Web of Science ®Google Scholar
• Kaelin WG Jr. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin. Cancer Res.10(18 Pt 2), 6290S–6295S (2004).
   PubMed Web of Science ®Google Scholar
• Kondo K , KaelinWG Jr. The von Hippel-Lindau tumor suppressor gene. Exp. Cell. Res.264(1), 117–125 (2001).
   PubMed Web of Science ®Google Scholar
• Pugh CW , RatcliffePJ. The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis. Semin. Cancer Biol.13(1), 83–89 (2003).
   PubMed Web of Science ®Google Scholar
• Lee SJ , LattoufJB, XanthopoulosJ, LinehanWM, BottaroDP, VasselliJR. von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1. Eur. Urol.54(4), 845–853 (2008).
   PubMed Web of Science ®Google Scholar
• Devita VTL , TheodoreS, Rosenberg, Steven A. Devita, Hellman & Rosenberg‘s Cancer: Principles & Practice of Oncology. Lippincott Williams & Wilkins, PA, USA, 4–8 (2008).
   Google Scholar
• Smaldone MC , MaranchieJK. Clinical implications of hypoxia inducible factor in renal cell carcinoma. Urol. Oncol.27(3), 238–245 (2009).
   PubMed Web of Science ®Google Scholar
• Furniss D , HardenP, AliN et al. Prognostic factors for renall cell carcinoma. Cancer Treat. Rev. 34, 407–426 (2008).
   PubMed Web of Science ®Google Scholar
• Smith K , GunaratnamL, MorleyM. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2 driven VHL-/- renal cancer. Cancer Res.65(12), 5221–5230 (2005).
   PubMed Web of Science ®Google Scholar
• Mitsudomi T , YatabeY. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J.277, 301–308 (2009).
   PubMedGoogle Scholar
• Yarden Y , SliwkowskiMX. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol.2(2), 127–137 (2001).
   PubMed Web of Science ®Google Scholar
• Olcay E , GiovannettiE, PetersG. Drug delivery and drug resistance: EGFR-tyrosine kinase inhibitors in non-small cell lung cancer. Open Lung Cancer J.3, 26–33 (2010).
   Google Scholar
• Liu W , InnocentiF, WuM et al. A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res. 65(1), 46–53 (2005).
   PubMed Web of Science ®Google Scholar
• Grandis J , SokJ. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol. Ther.102, 37–46 (2004).
   PubMed Web of Science ®Google Scholar
• Zhou L , YangH. The von Hippel-Lindau tumor suppressor protein promotes c-Cbl-independent poly-ubiquitylation and degradation of the activated EGFR. PLoS ONE6(9), e23936 (2011).
   PubMedGoogle Scholar
• Wang Y , RocheO, YanMS et al. Regulation of endocytosis via the oxygen-sensing pathway. Nat. Med. 15(3), 319–324 (2009).
   PubMed Web of Science ®Google Scholar
• Shen J , XiaW, KhotskayaYB et al. EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2. Nature 497(7449), 383–387 (2013).
   PubMed Web of Science ®Google Scholar
• Ravaud A , WallerandH, CulineS et al. Update on the medical treatment of metastatic renal cell carcinoma. Eur. Urol. 54(2), 315–325 (2008).
   PubMed Web of Science ®Google Scholar
• Rini BI , FlahertyK. Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma. Urol. Oncol.26(5), 543–549 (2008).
   PubMed Web of Science ®Google Scholar
• Ravaud A , Gross-GoupilM. Overcoming resistance to tyrosine kinase inhibitors in renal cell carcinoma. Cancer Treat. Rev.38(8), 996–1003 (2012).
   PubMed Web of Science ®Google Scholar
• Gambari R , FabbriE, BorgattiM et al. Targeting microRNAs involved in human diseases: a novel approach for modification of gene expression and drug development. Biochem. Pharmacol. 82(10), 1416–1429 (2011).
   PubMed Web of Science ®Google Scholar
• Zhang J , ZhaoH, GaoY, ZhangW. Secretory miRNAs as novel cancer biomarkers. Biochim. Biophys. Acta1826(1), 32–43 (2012).
   PubMed Web of Science ®Google Scholar
• Jansson MD , LundAH. MicroRNA and cancer. Mol. Oncol.6(6), 590–610 (2012).
   PubMed Web of Science ®Google Scholar
• Suzuki H , MaruyamaR, YamamotoE, KaiM. DNA methylation and microRNA dysregulation in cancer. Mol. Oncol.6(6), 567–578 (2012).
   PubMed Web of Science ®Google Scholar
• Pereira DM , RodriguesPM, BorralhoPM, RodriguesCM. Delivering the promise of miRNA cancer therapeutics. Drug Discov. Today18(5–6), 282–289 (2013).
   PubMed Web of Science ®Google Scholar
• Kusenda B , MrazM, MayerJ, PospisilovaS. MicroRNA biogenesis, functionality and cancer relevance. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech. Repub.150(2), 205–215 (2006).
   PubMedGoogle Scholar
• Catto JW , AlcarazA, BjartellAS et al. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur. Urol. 59(5), 671–681 (2011).
   PubMed Web of Science ®Google Scholar
• Chow TF , YoussefYM, LianidouE et al. Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. Clin. Biochem. 43(1–2), 150–158 (2010).
   PubMed Web of Science ®Google Scholar
• Marques I , TeixeiraAL, FerreiraM et al. Influence of survivin (BIRC5) and caspase-9 (CASP9) functional polymorphisms in renal cell carcinoma development: a study in a southern European population. Mol. Biol. Rep. 40(8), 4819–4826 (2013).
   PubMed Web of Science ®Google Scholar
• Cho WC . MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int. J. Biochem. Cell Biol.42(8), 1273–1281 (2010).
   PubMed Web of Science ®Google Scholar
• Duns G , van den Berg A, van Dijk MC et al. The entire miR-200 seed family is strongly deregulated in clear cell renal cell cancer compared with the proximal tubular epithelial cells of the kidney. Genes Chromosomes Cancer52(2), 165–173 (2012).
   PubMed Web of Science ®Google Scholar
• Cancer G enome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature499(7456), 43–49 (2013).
   PubMed Web of Science ®Google Scholar
• Zhang H , GuoY, ShangC, SongY, WuB. miR-21 downregulated TCF21 to inhibit KISS1 in renal cancer. Urology80(6), 1298–1302 (2012).
   PubMed Web of Science ®Google Scholar
• Cho WC . OncomiRs: the discovery and progress of microRNAs in cancers. Mol. Cancer6, 60 (2007).
   PubMed Web of Science ®Google Scholar
• Medina PP , NoldeM, SlackFJ. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature467(7311), 86–90 (2010).
   PubMed Web of Science ®Google Scholar
• Fu X , HanY, WuY et al. Prognostic role of microRNA-21 in various carcinomas: a systematic review and meta-analysis. Eur. J. Clin. Invest. 41(11), 1245–1253 (2011).
   PubMed Web of Science ®Google Scholar
• Pan X , WangZX, WangR. MicroRNA-21: a novel therapeutic target in human cancer. Cancer Biol. Ther.10(12), 1224–1232 (2010).
   PubMed Web of Science ®Google Scholar
• Liu LZ , LiC, ChenQ et al. MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1α expression. PLoS ONE 6(4), e19139 (2011).
   PubMed Web of Science ®Google Scholar
• Zhou X , RenY, MooreL et al. Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status. Lab. Invest. 90(2), 144–155 (2010).
   PubMed Web of Science ®Google Scholar
• Bruning U , CeroneL, NeufeldZ et al. MicroRNA-155 promotes resolution of hypoxia-inducible factor 1alpha activity during prolonged hypoxia. Mol. Cell. Biol. 31(19), 4087–4096 (2011).
   PubMed Web of Science ®Google Scholar
• Shinmei S , SakamotoN, GotoK et al. MicroRNA-155 is a predictive marker for survival in patients with clear cell renal cell carcinoma. Int. J. Urol. 20(5), 468–477 (2013).
   PubMed Web of Science ®Google Scholar
• Juan D , AlexeG, AntesT et al. Identification of a microRNA panel for clear-cell kidney cancer. Urology 75(4), 835–841 (2010).
   PubMed Web of Science ®Google Scholar
• Valera VA , WalterBA, LinehanWM, MerinoMJ. Regulatory effects of microRNA-92 (miR-92) on VHL gene expression and the hypoxic activation of miR-210 in clear cell renal cell carcinoma. J. Cancer2, 515–526 (2011).
   PubMed Web of Science ®Google Scholar
• Chan SY , LoscalzoJ. MicroRNA-210: a unique and pleiotropic hypoxamir. Cell Cycle9(6), 1072–1083 (2010).
   PubMed Web of Science ®Google Scholar
• Zhao A , LiG, Peoc‘hM, GeninC, GiganteM. Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Exp. Mol. Pathol.94(1), 115–120 (2013).
   PubMed Web of Science ®Google Scholar
• Zhang C , ZhangJ, HaoJ et al. High level of miR-221/222 confers increased cell invasion and poor prognosis in glioma. J. Transl. Med. 10(1), 119 (2012).
   PubMedGoogle Scholar
• Garofalo M , Di Leva G, Romano G et al. miR-221 and 222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell16(6), 498–509 (2009).
   PubMed Web of Science ®Google Scholar
• Shah M , CalinG. MicroRNAs miR-221 and miR-222: a new level of regulation in aggressive breast cancer. Genome Med.3(8), 56 (2011).
   PubMedGoogle Scholar
• Teixeira AL , GomesM, MedeirosR. EGFR signaling pathway and related-miRNAs in age-related diseases: the example of miR-221 and miR-222. Front. Genet.3(286), 7 (2012).
   PubMedGoogle Scholar
• Wulfken LM , MoritzR, OhlmannC et al. MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS ONE 6(9), e25787 (2011).
   PubMed Web of Science ®Google Scholar
• Ravi R , MookerjeeB, BhujwallaZM et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 14(1), 34–44 (2000).
   PubMed Web of Science ®Google Scholar
• Lou JJ , ChuaYL, ChewEH, GaoJ, BushellM, HagenT. Inhibition of hypoxia-inducible factor-1alpha (HIF-1alpha) protein synthesis by DNA damage inducing agents. PLoS ONE5(5), e10522 (2010).
   PubMedGoogle Scholar
• Redova M , PoprachA, NekvindovaJ et al. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J. Transl. Med. 10, 55 (2012).
   PubMed Web of Science ®Google Scholar
• Teixeira AL , SilvaJ, FerreiraM et al. Circulating microRNA-222 in plasma – a potencial biomarker for renal cell carcinoma. Eur. J. Cancer 48(Suppl. 5), S216 (2012).
   Web of Science ®Google Scholar
• Wettersten HI , WeissRH. Potential biofluid markers and treatment targets for renal cell carcinoma. Nat. Rev. Urol.10(6), 336–344 (2013).
   PubMed Web of Science ®Google Scholar
• Jung M , MollenkopfHJ, GrimmC et al. MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J. Cell. Mol. Med. 13(9B), 3918–3928 (2009).
   PubMed Web of Science ®Google Scholar
• Koturbash I , ZempFJ, PogribnyI, KovalchukO. Small molecules with big effects: the role of the microRNAome in cancer and carcinogenesis. Mutat. Res.722(2), 94–105 (2011).
   PubMed Web of Science ®Google Scholar
• Youssef YM , WhiteNM, GrigullJ et al. Accurate molecular classification of kidney cancer subtypes using microRNA signature. Eur. Urol. 59(5), 721–730 (2011).
   PubMed Web of Science ®Google Scholar
• Ma L . Role of miR-10b in breast cancer metastasis. Breast Cancer Res.12(5), 26 (2010).
   Google Scholar
• Park JK , KogureT, NuovoGJ et al. miR-221 silencing blocks hepatocellular carcinoma and promotes survival. Cancer Res. 71(24), 7608–7616 (2011).
   PubMed Web of Science ®Google Scholar
• Kota J , ChivukulaRR, O‘DonnellKA et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137(6), 1005–1017 (2009).
   PubMed Web of Science ®Google Scholar

▪ Website

• GeneCards®. www.genecards.org (Accessed 1March2013)
   Google Scholar